Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis

2001 ◽  
Vol 27 (1) ◽  
pp. 65-73 ◽  
Author(s):  
R.P. McQuellon ◽  
B.W. Loggie ◽  
R.A. Fleming ◽  
G.B. Russell ◽  
A.B. Lehman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Peritoneal Carcinomatosis ◽  
Intraperitoneal Hyperthermic Chemotherapy ◽  
Hyperthermic Chemotherapy

Long-Term Survivorship and Quality of Life After Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis

2003 ◽  
Vol 10 (2) ◽  
pp. 155-162 ◽  
Author(s):  
Richard P. McQuellon ◽  
Brian W. Loggie ◽  
Anna B. Lehman ◽  
Gregory B. Russell ◽  
Ronald A. Fleming ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Peritoneal Carcinomatosis ◽  
Cytoreductive Surgery ◽  
Intraperitoneal Hyperthermic Chemotherapy ◽  
Hyperthermic Chemotherapy

Intraperitoneal Hyperthermic Chemotherapy in Gastric Cancer: Rationale for a new Approach

1998 ◽  
Vol 84 (4) ◽  
pp. 483-488 ◽  
Author(s):  
Federico Bozzetti ◽  
Maurizio Vaglini ◽  
Marcello Deraco
Keyword(s):  
Gastric Cancer ◽  
Peritoneal Carcinomatosis ◽  
Intraperitoneal Chemotherapy ◽  
Randomized Clinical Trials ◽  
Locally Advanced ◽  
Preliminary Evidence ◽  
Favorable Effect ◽  
Tumor Spread ◽  
Intraperitoneal Hyperthermic Chemotherapy ◽  
Hyperthermic Chemotherapy

There is preliminary evidence from experience in the treatment of various abdominal malignancies that intraperitoneal chemotherapy alone or combined with hyperthermia may attain a role in the therapeutic strategy. This paper considers the rationale for such an approach, as well as its current results and potential indications in patients with gastric cancer. The literature is critically reviewed, with special emphasis on specific topics such as patterns of tumor spread, mechanisms of local recurrence, the rationale for intraperitoneal chemotherapy and intraperitoneal hyperthermic chemotherapy, toxicity, and results from non-controlled as well as randomized clinical trials in patients with gastric cancer. There is some evidence that intraperitoneal hyperthermic chemotherapy has a favorable effect on clinical outcome in patients with limited peritoneal carcinomatosis or malignant ascitis and in those at risk of future peritoneal spread, such as patients with pT3-pT4 cancers or with positive cytology of the peritoneal fluid. Hyperthermic chemotherapy should be considered a promising approach in limited or impending peritoneal carcinomatosis, and should be included in the multidisciplinary approach to the treatment of locally advanced gastric cancer.

scholarly journals Survival and Quality of Life Following Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colonic Origin

2011 ◽  
Vol 18 (13) ◽  
pp. 3673-3679 ◽  
Author(s):  
Adrienne R. Hill ◽  
Richard P. McQuellon ◽  
Gregory B. Russell ◽  
Perry Shen ◽  
John H. Stewart ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Peritoneal Carcinomatosis ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy

scholarly journals Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Hugo Teixeira Farinha ◽  
Fabian Grass ◽  
Amaniel Kefleyesus ◽  
Chahin Achtari ◽  
Benoit Romain ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cohort Study ◽  
Peritoneal Carcinomatosis ◽  
Retrospective Cohort ◽  
Negative Impact ◽  
Peritoneal Cancer ◽  
Before And After ◽  
Eortc Qlq C30 ◽  
Eortc Qlq

Background. Peritoneal cancer treatment aims to prolong survival, but preserving Quality of Life (QoL) under treatment is also a priority. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a novel minimally invasive repeatable treatment modality. The aim of the present study was to assess QoL in our cohort of PIPAC patients. Methods. Analysis of all consecutive patients included from the start of PIPAC program (January 2015). QoL (0–100: optimal) and symptoms (no symptom: 0–100) were measured prospectively before and after every PIPAC procedure using EORTC QLQ-C30. Results. Forty-two patients (M : F = 8 : 34, median age 66 (59–73) years) had 91 PIPAC procedures in total (1 : 4x, 17 : 3x, 12 : 2x, and 12 : 1x). Before first PIPAC, baseline QoL was measured as median of 66±2.64. Prominent complaints were fatigue (32±4.3) and digestive symptoms as diarrhea (17±3.75), constipation (17±4.13), and nausea (7±2.54). Overall Quality of Life was 64±3.75 after PIPAC#1 (p=0.57), 61±4.76 after PIPAC#2 (p=0.89), and 70±6.67 after PIPAC#3 (p=0.58). Fatigue symptom score was 44±4.86 after PIPAC#1 and 47±6.69 and 34±7.85 after second and third applications, respectively (p=0.40). Diarrhea (p=0.31), constipation (p=0.76), and nausea (p=0.66) did not change significantly under PIPAC treatment. Conclusion. PIPAC treatment of peritoneal carcinomatosis had no negative impact on patients’ overall QoL and its components or on main symptoms. This study was registered online on Research Registry (UIN: 1608).

scholarly journals The impact of hyperthermic intraperitoneal chemotherapy and cytoreductive surgery on clinical outcomes and quality of life of patients with peritoneal carcinomatosis

2021 ◽  
Author(s):  
Oleksandr Vadymovych Bondar ◽  
Serhii Hennadiiovych Chetverikov ◽  
Viacheslav Yevheniiovych Maksymovskyi ◽  
Dmytro Vadymovych Atanasov ◽  
Valeriia Volodymyrivna Chetverikova-Ovchynnyk ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Peritoneal Carcinomatosis ◽  
Clinical Outcomes ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
The Impact

Monitoring Health Outcomes Following Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis

2007 ◽  
Vol 14 (3) ◽  
pp. 1105-1113 ◽  
Author(s):  
Richard P. McQuellon ◽  
Suzanne C. Danhauer ◽  
Gregory B. Russell ◽  
Perry Shen ◽  
Joyce Fenstermaker ◽  
...  
Keyword(s):  
Health Outcomes ◽  
Peritoneal Carcinomatosis ◽  
Cytoreductive Surgery ◽  
Intraperitoneal Hyperthermic Chemotherapy ◽  
Hyperthermic Chemotherapy

scholarly journals Treatment of peritoneal carcinomatosis with Pressurized IntraPeritoneal Aerosol Chemotherapy – PIPAC-OPC2

2018 ◽  
Vol 3 (2) ◽  
Author(s):  
Martin Graversen ◽  
Sönke Detlefsen ◽  
Jon Asmussen ◽  
Bassam Mahdi ◽  
Claus Fristrup ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Peritoneal Carcinomatosis ◽  
Complete Response ◽  
Repeated Measurements ◽  
Improve Quality ◽  
Response Evaluation ◽  
Evaluation Tool ◽  
Open Label ◽  
Colorectal Origin

AbstractBackgroundPeritoneal carcinomatosis (PC) is a common endpoint in both gastrointestinal and non-gastrointestinal cancers, and PC is treated as other systemic metastases – unfortunately with disappointing results and considerable side-effects. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) is a new method of applying traditional chemotherapy, and preliminary data indicate that PIPAC is safe, able to stabilize or improve quality of life, and can induce an objectively measurable reduction in disease burden in PC.MethodsPIPAC-OPC2 is a prospectively controlled Phase II, single center, one-arm, open-label clinical trial investigating the treatment effect of PIPAC in patients with histological or cytological proven PC from gastrointestinal, ovarian or primary peritoneal cancer. Eligible patients will receive PIPAC in series of three using a combination of doxorubicin (1.5 mg/m2) and cisplatin (7.5 mg/m2) for non-colorectal cancer patients (PIPAC C/D), and oxaliplatin (92 mg/m2) in patients with PC of colorectal origin (PIPAC OX). Patients are monitored by: (1) repeated measurements of the Peritoneal Regression Grading Score (PRGS) in biopsies obtained from metal clips marked areas, (2) Quality-of-Life (QoL) questionnaires, (3) Magnetic Resonance Imaging (MRI) and (4) Prognostic Nutritional Index (PNI). Adverse events and surgical complications will be recorded according to the 30 days definition.ResultsThe primary outcome of PIPAC-OPC2 is to evaluate if PIPAC can induce major or complete response (PRGS 1 or 2) within a series of three PIPAC procedures. Secondarily this study investigates changes in QoL and MRI as a staging and response evaluation tool. The secondary outcomes will be used to create a model that may predict which of the patients will benefit from PIPAC treatment.ConclusionsIt is expected that PIPAC directed therapy can induce major or complete response in 50 % of patients with PC of colorectal origin and in 30 % of patients with PC of non-colorectal origin – and at the same time stabilize or even improve quality of life. This trial may provide data regarding the utility of MRI as a staging and response evaluation tool in patients with PC.Trial registrationThe study is registered with ClinicalTrials.gov Identifier NCT03287375 and the European Clinical Trials Database (EudraCT) number 2016-003394-18.

Sign in / Sign up

Export Citation Format

Share Document